Veradermics reports Q3 2026 results, $798.4 million cash, runway into 2030
Company says cash funds operations into 2030 through multiple Phase 3 readouts and potential launch of VDPHL01, with female pattern hair loss data due in 1H27.
SEC filing (3)
1 story
Company says cash funds operations into 2030 through multiple Phase 3 readouts and potential launch of VDPHL01, with female pattern hair loss data due in 1H27.
SEC filing (3)